Cellectis (NASDAQ:CLLS) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS) in a report published on Sunday. The firm issued a sell rating on the biotechnology company’s stock.

Several other equities research analysts have also issued reports on the company. JMP Securities reiterated a market outperform rating and set a $6.00 price target on shares of Cellectis in a report on Friday, May 31st. Oppenheimer reduced their target price on Cellectis from $11.00 to $10.00 and set an outperform rating for the company in a report on Wednesday, June 12th.

Cellectis Stock Up 0.5 %

Shares of Cellectis stock opened at $1.87 on Friday. The firm has a market cap of $103.94 million, a price-to-earnings ratio of -1.45 and a beta of 3.09. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.63 and a quick ratio of 1.63. Cellectis has a 52-week low of $0.96 and a 52-week high of $3.77. The stock has a 50-day simple moving average of $2.61 and a 200-day simple moving average of $2.75.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings results on Tuesday, May 28th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter. The firm had revenue of $6.50 million for the quarter. Cellectis had a negative net margin of 529.81% and a negative return on equity of 67.41%. On average, equities research analysts expect that Cellectis will post -0.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cellectis

An institutional investor recently raised its position in Cellectis stock. Principal Financial Group Inc. increased its stake in Cellectis S.A. (NASDAQ:CLLS) by 6.2% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 424,533 shares of the biotechnology company’s stock after purchasing an additional 24,906 shares during the quarter. Principal Financial Group Inc. owned approximately 0.76% of Cellectis worth $1,125,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.